Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Publication year range
1.
Arterioscler Thromb Vasc Biol ; 28(5): 940-6, 2008 May.
Article in English | MEDLINE | ID: mdl-18292393

ABSTRACT

OBJECTIVE: The purpose of this study was to investigate whether thoracic ascending aortic aneurysm (TAAA) induces platelet activation as mural thrombus participates in aortic dilatation in abdominal aortic aneurysm and TAAA are associated with rheological factors favoring coagulation activation. METHODS AND RESULTS: We studied the relation between coagulation activation and aortic diameter in Marfan patients (MFS) with various aortic diameters (n=52). We then studied patients presenting large aneurysms associated with bicuspid aortic valve (BAV) and degenerative form. Lastly, we used immunochemistry and biochemistry to investigate prothrombin/thrombin retention within the aortic wall. Microparticles, sGPV, tissue factor, and TAT complexes were increased in plasma from MFS with large aneurysms (>or=45 mm) compared to MFS with limited aortic dilatation (<45 mm). Similar elevations were observed in all patients with large aortic aneurysms, regardless of the etiology, the site of maximal aortic dilation, associated valvulopathy, risk factors, or treatments. P-selectin and platelet-bound fibrinogen were also increased, demonstrating platelet activation in large aneurysms. Significant increase in sCD146 plasma concentration suggested alteration of endothelium. CONCLUSIONS: Platelet activation occurs in patients with large aneurysms of the ascending aorta, is dependent on aortic dilation, and is associated with thrombin generation, part of which appears to be retained in mucoid degeneration areas.


Subject(s)
Aorta, Thoracic/pathology , Aortic Aneurysm, Thoracic/pathology , Aortic Aneurysm, Thoracic/physiopathology , Platelet Activation/physiology , Prothrombin/metabolism , Vasodilation/physiology , Adult , Aged , Aortic Aneurysm, Thoracic/etiology , C-Reactive Protein/metabolism , CD146 Antigen/metabolism , CD40 Ligand/metabolism , Case-Control Studies , Endothelium, Vascular/metabolism , Endothelium, Vascular/pathology , Endothelium, Vascular/physiopathology , Female , Fibrinogen/metabolism , Humans , Male , Marfan Syndrome/complications , Marfan Syndrome/metabolism , Marfan Syndrome/physiopathology , Middle Aged , P-Selectin/metabolism , Thrombin/metabolism , Vascular Cell Adhesion Molecule-1/metabolism
2.
Ann Cardiol Angeiol (Paris) ; 57(1): 16-21, 2008 Feb.
Article in French | MEDLINE | ID: mdl-18054343

ABSTRACT

INTRODUCTION: Hypertrophic cardiomyopathy is an inherited disease characterized by a left ventricular hypertrophy, a diastolic dysfunction and rhythm troubles with risk of sudden death. There was an evolution in the surgical strategy to treat the patients who present a left ventricular outflow tract gradient. MATERIALS AND METHODS: A retrospective study was conducted: We selected eight cases who presented an hypertrophic cardiomyopathy and operated on. Pre and post operative echocardiographic data were analysed. Follow up was obtained by call or mail to the cardiologist. RESULTS: The patients were classified in four groups: isolated left ventricular outflow tract obstruction, left ventricular outflow tract obstruction and associated lesions, obstructive hypertrophic cardiomyopathy and endocarditis, post operative complications of the hypertrophic cardiomyopathy surgery. We observed a significant decrease of the left ventricular outflow tract mean gradient in the post operative period and at four years. CONCLUSION: Surgical management of obstructive hypertrophic cardiomyopathy remain an important option in young patients, in case of failure of the ethanol septal ablation or in patients who present other surgical lesions. The dual chamber stimulation remain indicated in old patients.


Subject(s)
Cardiomyopathy, Hypertrophic/surgery , Adult , Aged , Cardiomyopathy, Hypertrophic/complications , Extracorporeal Circulation , Female , Heart Septum/surgery , Humans , Male , Middle Aged , Retrospective Studies , Treatment Outcome , Ventricular Outflow Obstruction/etiology , Ventricular Outflow Obstruction/surgery
3.
Eur J Cardiothorac Surg ; 32(1): 96-101, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17512209

ABSTRACT

OBJECTIVE: Although it is known that the papillary muscles ensure the continuity between the left ventricle (LV) and the mitral apparatus, their precise mechanism needs further study. We hypothesize that the papillary muscles function as shock absorbers to maintain a constant distance between their tips and the mitral annulus during the entire cardiac cycle. MATERIALS AND METHODS: Sonomicrometry crystals were implanted in five sheep in the mitral annulus at the trigones (T1 and T2), mid anterior annulus (AA) mid posterior annulus (PA), base of the posterior lateral scallops (P1 and P2), tips of papillary muscles (M1 and M2), and LV apex. LV and aortic pressures were simultaneously recorded and used to define the different phases of the cardiac cycle. RESULTS: No significant distance changes were found during the cardiac cycle between each papillary muscle tip and their corresponding mitral hemi-annulus: M1-T1, (3.5+/-2%); M1-P1 (5+/-2%); M1-PA (5+/-3%); M2-T2 (2.7+/-2%); M2-P2 (6.1+/-3%); and M2-AA (4.2+/-3%); (p>0.05, ANOVA). Significant changes were observed in distances between each papillary muscle tip and the contralateral hemi-mitral annulus: M1-T2 (1.7+/-3%); M1-P2 (23+/-6%); M1-AA (6+/-3%); M2-T1 (8+/-3%); M2-P1 (10.5+/-6%); and M2-PA (12.6+/-8%); (p<0.05 ANOVA). The distance changes between LV apex and each papillary muscle tip were significantly different: apex-M1 (12.9+/-1%) and apex-M2 (10.5+/-1%) and different from the averaged distance change between the LV apex and each annulus crystal (8.3+/-1%) with p<0.05. CONCLUSION: The papillary muscles seem to be independent mechanisms designed to work as shock absorbers to maintain the basic mitral valve geometry constant during the cardiac cycle.


Subject(s)
Mitral Valve/physiology , Papillary Muscles/physiology , Animals , Aorta/physiology , Biomechanical Phenomena , Blood Pressure/physiology , Myocardial Contraction/physiology , Sheep , Ventricular Function, Left/physiology
4.
Eur Heart J ; 26(13): 1333-41, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15827062

ABSTRACT

AIMS: Aortic valve diseases are characterized by pathological remodelling of valvular tissue but the cellular and molecular effectors involved in these processes are not well known. The role of matrix metalloproteinase (MMP)-2, MMP-9, MMP-3, MMP-7, and tissue inhibitor of matrix metalloproteinase (TIMP)-1 and TIMP-2 are investigated here. METHODS AND RESULTS: Histological analysis of pathological valves [aortic stenosis (AS) (n=49), aortic regurgitation (AR) (n=23)] and control valves (n=8) was performed. The main tissue abnormalities (calcification, inflammatory cells, and capillaries) observed in AS were less severe or absent in AR. However, both groups of pathological valves displayed similar histological signs of extracellular matrix (ECM) remodelling. Biochemical analysis of MMPs and TIMPs (gelatin and casein zymography and ELISA) was performed on valve extracts. MMP-2 activity was not significantly different in control and pathological valves. Increases in MMP-9 and MMP-3 in AS demonstrated an inflammatory state. Finally, there was a four- to seven-fold increase of TIMP-1 in pathological valves. TIMP-1, TIMP-2, and MMP-2 were synthesized by the valvular interstitial cells in primary culture. CONCLUSION: This study demonstrates the involvement of the MMP/TIMP system in ECM remodelling of both AS and AR. These findings provide evidence of inflammatory injury more severe in AS than in AR and involvement of mesenchymal cell response.


Subject(s)
Aortic Valve Insufficiency/pathology , Aortic Valve Stenosis/pathology , Extracellular Matrix/pathology , Matrix Metalloproteinases/physiology , Tissue Inhibitor of Metalloproteinases/physiology , Adult , Aortic Valve Insufficiency/enzymology , Aortic Valve Stenosis/enzymology , Case-Control Studies , Cells, Cultured , Enzyme-Linked Immunosorbent Assay , Female , Humans , Male , Matrix Metalloproteinases/metabolism , Middle Aged , Tissue Inhibitor of Metalloproteinases/metabolism
5.
Hypertension ; 39(2): 209-13, 2002 Feb.
Article in English | MEDLINE | ID: mdl-11847185

ABSTRACT

A gene polymorphism of preproendothelin-1 (a G-to-T transversion that predicts a Lys/Asn change at codon 198) associated with an increased risk of hypertension has been recently described in patients carrying the T allele. No study has yet determined the impact of this polymorphism on vascular reactivity, although a functional role for endothelin-1 in the pathophysiology of hypertension has been clarified. At subthreshold concentrations, endothelin-1 and angiotensin II induce a potentiation of alpha-adrenergic-dependent vascular tone caused by an increased sensitivity of the contractile apparatus to calcium. We investigated phenylephrine-induced tone and its amplification by endothelin-1 and angiotensin II in human mammary artery rings in vitro. Contractions to phenylephrine (0.1 to 100 micromol) and endothelin-1 (0.1 to 300 nmol) were not significantly different in rings from GT/TT (n=27) and GG (n=21) patients. A subthreshold concentration of endothelin-1 (10 pmol) potentiated a phenylephrine-induced contraction (eg, 44 +/- 12% increase in tone with phenylephrine 1 micromol/L, P<0.001) that was significantly higher in the GT/TT group than in the GG group (eg, 44 +/- 12% versus 82 +/- 11%, P<0.01). A similar effect on response to phenylephrine was observed with a subthreshold concentration of angiotensin II. We also found a higher response to calcium in arteries from GT/TT patients. Endothelium-dependent or -independent relaxations were unaffected by the genotype. These data suggest that the preproendothelin-1 gene polymorphism is associated with a higher potentiating effect of endothelin-1 and angiotensin II, probably in relation with higher calcium sensitivity. These changes in vascular reactivity might help to understand the relations between this polymorphism and cardiovascular disorders.


Subject(s)
Endothelins/genetics , Mammary Arteries/physiology , Protein Precursors/genetics , Vasoconstriction/physiology , Acetylcholine/pharmacology , Aged , Angiotensin II/pharmacology , Dose-Response Relationship, Drug , Drug Synergism , Endothelin-1/pharmacology , Female , Genotype , Humans , In Vitro Techniques , Male , Mammary Arteries/drug effects , Middle Aged , Nitroprusside/pharmacology , Phenylephrine/pharmacology , Polymorphism, Genetic , Vasoconstriction/drug effects , Vasoconstriction/genetics , Vasoconstrictor Agents/pharmacology , Vasodilation/drug effects , Vasodilator Agents/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...